RET Fusion-Positive Solid Tumor

Kenji Kawada

RET Fusion-Positive Solid Tumor

Kenji Kawada

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

Selpercatinib, a RET inhibitor, is covered by insurance for all solid tumors that are positive for the RET fusion gene. The RET fusion gene is positive in 2% of lung cancers and 10-20% of papillary thyroid cancers. In other solid tumors, positivity is less than 0.5%. However, if positive, treatment is expected to be effective, so it is desirable to actively perform cancer gene panel testing.

本文言語	英語
ページ（範囲）	323-326
ページ数	4
ジャーナル	Japanese Journal of Cancer and Chemotherapy
巻	53
号	5
出版ステータス	出版済み - 01-05-2026
外部発表	はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

腫瘍学
癌研究

他のファイルとリンク

引用スタイル

@article{68470a9a5a3f4d7d9125aa94ce6dd79c,

title = "RET Fusion-Positive Solid Tumor",

abstract = "Selpercatinib, a RET inhibitor, is covered by insurance for all solid tumors that are positive for the RET fusion gene. The RET fusion gene is positive in 2\% of lung cancers and 10-20\% of papillary thyroid cancers. In other solid tumors, positivity is less than 0.5\%. However, if positive, treatment is expected to be effective, so it is desirable to actively perform cancer gene panel testing.",

author = "Kenji Kawada",

year = "2026",

month = may,

day = "1",

language = "English",

volume = "53",

pages = "323--326",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "5",

}

TY - JOUR

T1 - RET Fusion-Positive Solid Tumor

AU - Kawada, Kenji

PY - 2026/5/1

Y1 - 2026/5/1

N2 - Selpercatinib, a RET inhibitor, is covered by insurance for all solid tumors that are positive for the RET fusion gene. The RET fusion gene is positive in 2% of lung cancers and 10-20% of papillary thyroid cancers. In other solid tumors, positivity is less than 0.5%. However, if positive, treatment is expected to be effective, so it is desirable to actively perform cancer gene panel testing.

AB - Selpercatinib, a RET inhibitor, is covered by insurance for all solid tumors that are positive for the RET fusion gene. The RET fusion gene is positive in 2% of lung cancers and 10-20% of papillary thyroid cancers. In other solid tumors, positivity is less than 0.5%. However, if positive, treatment is expected to be effective, so it is desirable to actively perform cancer gene panel testing.

UR - https://www.scopus.com/pages/publications/105041243297

UR - https://www.scopus.com/pages/publications/105041243297#tab=citedBy

M3 - Article

C2 - 42237507

AN - SCOPUS:105041243297

SN - 0385-0684

VL - 53

SP - 323

EP - 326

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 5

ER -

RET Fusion-Positive Solid Tumor

抄録

UN SDG

All Science Journal Classification (ASJC) codes

他のファイルとリンク

フィンガープリント

引用スタイル